摘要
目的:观察氨溴特罗联合布地奈德治疗急性支气管炎患儿的效果。方法:选取2021年9月至2022年9月该院收治的90例急性支气管炎患儿进行前瞻性研究,应用随机数字表法将其分为对照组和观察组各45例。对照组采用布地奈德治疗,观察组在对照组基础上采用氨溴特罗治疗,比较两组临床疗效、临床症状改善时间、治疗前后炎性因子[白细胞介素(IL)-2、IL-4、IL-6]水平、肺功能指标[呼气峰值流速(PEF)、最大通气量(MVV)、呼吸频率]水平和治疗期间不良反应发生率。结果:观察组治疗总有效率为95.56%(43/45),高于对照组的75.56%(34/45),差异有统计学意义(P<0.05);观察组退热时间、止咳时间、气喘缓解时间、肺部啰音消失时间均短于对照组,差异有统计学意义(P<0.05);治疗后,观察组IL-2水平高于对照组,IL-4和IL-6水平均低于对照组,差异有统计学意义(P<0.05);治疗后,观察组PEF和MVV水平均高于对照组,呼吸频率低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:氨溴特罗联合布地奈德治疗急性支气管炎患儿可提高治疗总有效率,改善炎性因子和肺功能指标水平,缩短临床症状改善时间,效果优于单纯布地奈德治疗。
Objective:To observe effects of Ambroxol hydrochloride and Clenbuterol hydrochloride combined with Budesonide in treatment of children with acute bronchitis.Methods:A prospective study was conducted on 90 children with acute bronchitis admitted to this hospital from September 2021 to September 2022.They were divided into control group and observation group by using the random number table method,45 cases in each group.The control group was treated with Budesonide,while the observation group was treated with Ambroxol hydrochloride and Clenbuterol hydrochloride on the basis of that of the control group.The clinical efficacy,the improvement time of clinical symptoms,the levels of inflammatory factors[interleukin(IL)-2,IL-4,IL-6],the lung function index levels[peak expiratory flow(PEF),maximum ventilation volume(MVV),respiratory rate]before and after the treatment,and incidence of adverse reactions during treatment were compared between the two groups.Results:The total effective rate of treatment in the observation group was 95.56%(43/45),which was higher than 75.56%(34/45)in the control group,and the difference was statistically significant(P<0.05).The antipyretic time,the cough relief time,the asthma relief time and the lung rale disappearance time in the observation group were shorter than those in the control group,the differences were statistically significant(P<0.05).After the treatment,the level of IL-2 in the observation group was higher than that in the control group,the levels of IL-4 and IL-6 were lower than those in the control group,and the differences were statistically significant(P<0.05).Further,after the treatment,the levels of PEF and MVV in the observation group were higher than those in the control group,the respiratory rate was lower than that in the control group,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Ambroxol hydrochloride and Clenbuterol hydrochloride combined with Budesonide in the treatment of the children with acute bronchitis can improve the total effective rate of treatment,improve the levels of inflammatory factors and lung function indexes,and shorten the improvement time of clinical symptoms.Moreover,it is superior to single Budesonide treatment.
作者
康萍萍
张小珍
陈晓伟
KANG Pingping;ZHANG Xiaozhen;CHEN Xiaowei(Department of Pharmacy of Xinfeng County Maternal and Child Health Hospital,Ganzhou 341600 Jiangxi,China)
出处
《中国民康医学》
2023年第15期59-61,65,共4页
Medical Journal of Chinese People’s Health
关键词
急性支气管炎
儿童
布地奈德
氨溴特罗
炎性因子
肺功能
不良反应
Acute bronchitis
Children
Budesonide
Ambroxol hydrochloride and Clenbuterol hydrochloride
Inflammatory factor
Lung function
Adverse reaction
